High SHP2 expression determines the efficacy of PD-1/PD-L1 inhibitors in advanced KRAS mutant non-small cell lung cancer,Thoracic Cancer

当前位置： X-MOL 学术 › Thorac. Cancer › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

High SHP2 expression determines the efficacy of PD-1/PD-L1 inhibitors in advanced KRAS mutant non-small cell lung cancer
Thoracic Cancer ( IF 2.3 ) Pub Date : 2021-09-06 , DOI: 10.1111/1759-7714.14137
Hui-Bo Feng ₁ , Yu Chen ₁ , Zhi Xie ₁ , Jie Jiang ₁ , Yu-Min Zhong ₁ , Wei-Bang Guo ₁ , Wen-Qing Yan ₁ , Zhi-Yi Lv ₁ , Dan-Xia Lu ₁ , Hong-Ling Liang ₂ , Fang-Ping Xu ₃ , Jin-Ji Yang _{1,

4} , Xue-Ning Yang ₁ , Qing Zhou _{1,

4} , Dong-Kun Zhang ₅ , Zhou Zhang ₆ , Shao-Kun Chuai ₆ , Heng-Hui Zhang ₇ , Yi-Long Wu _{1,

4} , Xu-Chao Zhang ₁

Affiliation

Src homology region 2 domain-containing phosphatase 2 (SHP2) is a novel target for Kirsten rat sarcoma oncogene (KRAS) mutant cancer. We retrospectively studied the significance of SHP2 in KRAS mutant non-small cell lung cancer (NSCLC) treated with immunotherapy and its relationship with tumor microenvironment (TME).

中文翻译：

SHP2 的高表达决定了 PD-1/PD-L1 抑制剂在晚期 KRAS 突变非小细胞肺癌中的疗效

含有 Src 同源区 2 结构域的磷酸酶 2 (SHP2) 是 Kirsten 大鼠肉瘤癌基因 (KRAS) 突变癌症的新靶点。我们回顾性研究了 SHP2 在 KRAS 突变型非小细胞肺癌 (NSCLC) 免疫治疗中的意义及其与肿瘤微环境 (TME) 的关系。

更新日期：2021-10-04

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11